Global Biliary Tract Cancer Market Spotlight 2017: Eli Lily has Carried out the Most Phase II Trials in Biliary Tract Neoplasms Space, Followed by Sanofi and AstraZeneca
DUBLIN, Feb. 15, 2018 /PRNewswire/ --
The "Market Spotlight: Biliary Tract Cancer" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This Market Spotlight report covers the Biliary Tract Cancer market, comprising key pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Key Takeaways
-- The author estimates that in 2016, there were approximately 716,000
incident cases of biliary tract cancer worldwide, and forecasts that
number to increase to 784,000 incident cases by 2025.
-- The majority of industry-sponsored drugs in active clinical development
for biliary tract cancer are in Phase II. Therapies in mid-to-late-stage
development for biliary tract cancer focus on a wide variety of targets,
with the majority being administered via the oral route.
-- High-impact upcoming events include topline Phase III trial results for
derazantinib. There were only three licensing and asset acquisition
activities involving gallbladder and biliary tract cancer drugs during
2012-17. The exclusive acquisition agreement signed in 2017 between
Mundipharma and CellAct for $250m for the acquisition of CAP7-1 was the
only deal with disclosed deal value during the period.
-- The clinical trials distribution across Phase I-IV indicates that the
majority of trials for biliary tract neoplasms been in the early and
mid-phases of development, with 94% of trials in Phase I-II, and only 6%
in Phase III.
-- The US has a substantial lead in the number of biliary tract neoplasms
clinical trials globally. The UK leads the major EU markets, while Japan
has the top spot in Asia.
-- Clinical trial activity in the biliary tract neoplasms space is
dominated by completed trials. AstraZeneca, Eli Lilly and Sanofi have
the highest number of completed clinical trials for biliary tract
neoplasms, with three completed trials each.
-- Eli Lily has carried out the most Phase II trials in biliary tract
neoplasms space, followed by Sanofi and AstraZeneca
Key Topics Covered:
KEY TAKEAWAYS
DISEASE BACKGROUND
Biliary Tract Cancer Subtypes
TREATMENT
Surgery
Radiation Therapy
Chemotherapy
Palliative Therapy
EPIDEMIOLOGY
PIPELINE DRUGS
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
Mundipharma Acquires 'Smart' Chemo Drug From CellAct
PARENT PATENTS
CLINICAL TRIAL LANDSCAPE
Recent events
BIBLIOGRAPHY
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/7785gt/global_biliary?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
